Skip to main content
Caplight Logo









Marengo Therapeutics

Marengo Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://marengotx.com/

Last Round

Series B

Nov 8, 2021

Total Funding Raised

$119M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Marengo Therapeutics is a biotechnology company that develops precision immunotherapies for cancer and autoimmune diseases through its proprietary T-cell activation platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

immunotherapysolid tumorsT cell activationbiotechcancer drugcheckpoint inhibitorclinical stage biotechantibody engineeringcombo therapytumor microenvironmentdrug pipelineoncologybiopharmaclinical trial

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Marengo Therapeutics Comparables

Compare Marengo Therapeutics with similar companies based on industry and business-model similarity.

Marengo Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Normunity
84%
Repertoire Immune Medicines
82%
Crossbow Therapeutics
78%

Marengo Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BNov 8, 2021
Series AJan 3, 2018

Key People

Founding team and executive leadership

Svetlana Ni Makhni

Chief Financial Officer

Executive Team

Marengo Therapeutics Investors

Notable investors and investment history

Marengo Therapeutics investors
InvestorRounds
Apple Tree PartnersSeries B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors grew 122% MoM, reaching 4.9K.

  • Apr 17, 2026

    Unveiled partnered STAR program IPN01203/STAR0501, now in Phase 1 trials.

Recent news

Latest coverage and updates

  • hiresAug 6, 2026

    Marengo Therapeutics, Inc. hired Saso Cemerski as senior vice president, head of immunology on Aug 6th '26.

Marengo Therapeutics Filings

Explore SEC and related filing metadata, where available.

Marengo Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Marengo Therapeutics's valuation, stock price, and market status.

Is Marengo a public or private company?

Marengo is a private company.

What is the current stock price of Marengo?

Marengo is a private company with no public stock price. No recent secondary market data is available.

How much is Marengo worth (valuation)?

Valuation information for Marengo is not publicly available.

Can I buy Marengo stock?

Marengo shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Marengo's last funding round?

Marengo's most recent funding round was Series A on November 8, 2021.

Who are the main investors in Marengo?

Key investors in Marengo include Apple Tree Partners.

Will Marengo IPO soon?

No public IPO plans have been announced for Marengo.

How can I track Marengo secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Marengo's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range34
Year Founded2015
Last FundingNov 8, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?